Ra Pharmaceuticals (NASDAQ:RARX)‘s stock had its “buy” rating reissued by Royal Bank Of Canada in a research report issued on Tuesday. They presently have a $18.00 price objective on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 141.61% from the stock’s current price.
RARX has been the topic of a number of other research reports. Zacks Investment Research upgraded Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 5th. Credit Suisse Group increased their target price on Ra Pharmaceuticals from $19.00 to $23.00 and gave the company an “outperform” rating in a report on Friday, November 10th. BMO Capital Markets increased their target price on Ra Pharmaceuticals in a report on Tuesday. Finally, Jefferies Group reiterated a “buy” rating and set a $25.00 target price on shares of Ra Pharmaceuticals in a report on Thursday, September 28th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $23.20.
Shares of Ra Pharmaceuticals (NASDAQ:RARX) opened at $7.45 on Tuesday. Ra Pharmaceuticals has a fifty-two week low of $7.31 and a fifty-two week high of $27.84.
Hedge funds have recently bought and sold shares of the company. Candriam Luxembourg S.C.A. boosted its holdings in shares of Ra Pharmaceuticals by 43.2% during the third quarter. Candriam Luxembourg S.C.A. now owns 116,000 shares of the company’s stock worth $1,694,000 after purchasing an additional 35,000 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Ra Pharmaceuticals by 70.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 21,800 shares of the company’s stock worth $409,000 after purchasing an additional 9,000 shares during the last quarter. Nationwide Fund Advisors boosted its holdings in shares of Ra Pharmaceuticals by 1,078.4% during the second quarter. Nationwide Fund Advisors now owns 32,842 shares of the company’s stock worth $615,000 after purchasing an additional 30,055 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Ra Pharmaceuticals by 33.7% during the second quarter. JPMorgan Chase & Co. now owns 199,900 shares of the company’s stock worth $3,746,000 after purchasing an additional 50,432 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Ra Pharmaceuticals during the third quarter worth $4,664,000. Institutional investors and hedge funds own 69.64% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Royal Bank Of Canada Reiterates Buy Rating for Ra Pharmaceuticals (RARX)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3078709/royal-bank-of-canada-reiterates-buy-rating-for-ra-pharmaceuticals-rarx.html.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.